ArticleeNeurologicalSci2022

Favorable benefit-risk ratio with teriflunomide treatment in relapsing-remitting multiple sclerosis: Results of the 2-year, multicenter, prospective, noninterventional TAURUS MS study in Austria.

Michael Guger et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.